Johnson & Johnson resumes European rollout after regulator says benefits outweigh blood clot risk
New York, April 21 (RHC)-- Phama giant Johnson & Johnson is resuming its rollout in Europe after the EU drugs regulator said the vaccine may be linked to extremely rare blood clots but that its benefits far outweigh its risks.
The European regulator said the vaccine should carry a warning. It will be up to individual EU countries to decide whether and how to distribute the J&J vaccine.
On Friday, a panel for the Centers for Disease Control and Prevention is meeting to make recommendations on its use in the United States, which has been temporarily halted.